Warehousing confusion as Amazon cuts space allocations pre-peak
After some easing earlier in the year, warehousing constraints and pricing in the US appear ...
MAERSK: BOTTOM FISHING NO MOREDHL: IN THE DOCKHLAG: GREEN DEALXOM: GEOPOLITICAL RISK AND OIL REBOUND IMPACTZIM: END OF STRIKE HANGOVERCHRW: GAUGING UPSIDEBA: STRIKE RISKDSV: STAR OF THE WEEKDSV: FLAWLESS EXECUTIONKNIN: ANOTHER LOWWTC: TAKING PROFITMAERSK: HAMMEREDZIM: PAINFUL END OF STRIKE
MAERSK: BOTTOM FISHING NO MOREDHL: IN THE DOCKHLAG: GREEN DEALXOM: GEOPOLITICAL RISK AND OIL REBOUND IMPACTZIM: END OF STRIKE HANGOVERCHRW: GAUGING UPSIDEBA: STRIKE RISKDSV: STAR OF THE WEEKDSV: FLAWLESS EXECUTIONKNIN: ANOTHER LOWWTC: TAKING PROFITMAERSK: HAMMEREDZIM: PAINFUL END OF STRIKE
Well-documented fears from incumbents that Amazon has set its sights on the pharmaceutical market have been waylaid – for now at least. The news follows its admission to regulators that it will not use its pharmacy licences to sell prescriptions, but to sell medical devices and supplies instead. The etailer had gained licences from Tennessee and Indiana – but analyst Jeffries, through a freedom of information request, discovered that its application stated it would “not store or ship drugs”. Neverthless, it may perhaps have opted for “lower-hanging fruit” first, before it moves into the drug market. However, an analyst at Pembroke Consulting believes that the pharma market could be a tough one to crack, even for Amazon.
Comment on this article